B+
Bull case
20%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
IMNN
ImunonANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-10-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+83.9
Score
AI commentary
Company clinical updates are constructive, but the September financing filing reinforces balance-sheet caution. No verified post-update price reaction, current analyst revisions, or sufficient social, options, short-interest or employee-review measures were supplied; numerical zeros above denote unavailable data, not neutral readings. The available ovarian-cancer comparators differ materially in disease setting, development stage or mechanism and cannot validate IMNN's valuation. With a negative deterministic directional prior, this remains a tentative, low-coverage monitoring view.
RankAlpha Sentiment Codex - 2026-10-09
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31catalystFinancing terms and cash-runway scrutinyHigh impact
A September 28 agreement exchanged $1.2 million of secured-note principal, plus accrued interest, for non-convertible Series B preferred stock carrying an 8% annual return. This reduces note obligations but adds a preferred claim; it is not new cash. June 30 cash was $6.9 million against $7.0 million of first-half operating cash use. Further funding terms could materially affect common shareholders. [#8-K-2026-09-29] SEC filing; Q2 release filed as Exhibit 99.1.
2027-06-30eventMRD study maturationHigh impact
The independent monitoring committee recommended that the Phase 2 MRD study continue without modification. Preliminary response comparisons involved only nine assessed patients per arm and cannot establish efficacy; larger follow-up may strengthen or weaken the signal. No readout date was announced, so the date here is a monitoring horizon, not company guidance. [#PR-2026-09-22] Company release.
2029-03-31catalystOVATION 3 enrollment and survival confirmationHigh impact
At its September R&D Day, Imunon reported enrollment of about 0.5 patients per site per month versus a 0.3 planning assumption and targeted completion in Q1 2029. The approximately 500-patient Phase 3 trial must confirm the 14.7-month median overall-survival difference seen in OVATION 2, which was not powered for survival. Two interim analyses are event-driven, with no disclosed dates. [#PR-2026-09-24] Company R&D Day update.
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-09 • Updated nightlySource: Internal modelMethodology